Market Cap
$194.3M
PYXS
Pyxis Oncology, Inc.
$2.14 ▼ -2.28%
Prev close $2.19Market cap$194.3M
ConsensusStrong Buy
12-mo target$8.67 (+305.0%)
▲ Bullish
Analyst conviction 9/10
11 New Institutional Positions4 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on PYXS right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Analyst Consensus
Strong Buy (88%)
Inst. Holders
50 funds
Inst. Value
$26.0M
Inst. Activity
11 buys / 4 sells
Insider Activity
$0.00 buy / $123.0K sell
Insider Net $
-$123.0K
SEC Reports
9
Press Releases
3
Price chart 30d -40.0%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 2, 2026 offering
Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering
BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS or the “Company”), a cl
Oct 1, 2026 Insider
GordonMD Global Investments LP bought 7,546,766 shares
10%+ Owner
Oct 1, 2026 Insider
Sep 9, 2026 SEC GordonMD Global Investments LP bought 5,517,000 shares
10%+ Owner
Pyxis Oncology appointed interim CEO Thomas Civik as permanent CEO and Chairman, replacing John Flavin who becomes Lead
8-K — Impact 3/10
Pyxis Oncology announced positive updated Phase 1 monotherapy data for micvotabart pelidotin (MICVO) in second-line and
8-K — Impact 6/10
Sep 4, 2026 Insider
Aug 28, 2026 SEC Civik Thomas was granted 2,503,050 shares
CEO & Chairman of the Board
Pyxis Oncology's S-3 shelf registration (File No. 333-298461) became effective on August 27, 2026, allowing the company
EFFECT — Impact 6/10
Pyxis Oncology announced a $50M private placement (plus up to $64M from warrants) led by BVF Partners, extending cash ru
Impact 6/10
Analyst ratings buy % +1.1%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
88% rate it Buy or better · 16 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 10, 2026 | Wedbush | MAINTAIN | Outperform | 57% |
| Sep 10, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Sep 9, 2026 | Wells Fargo | MAINTAIN | Overweight | 54% |
| Aug 18, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Aug 3, 2026 | Wells Fargo | INITIATE | Overweight | 54% |
| Jul 2, 2026 | Leerink Partners | MAINTAIN | Outperform | 49% |
| May 5, 2026 | Wedbush | INITIATE | Outperform | 57% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 7 | 7 | 2 | 0 | 0 | 88% | |
| Aug 1, 2026 | 7 | 6 | 2 | 0 | 0 | 87% | |
| Jul 1, 2026 | 7 | 6 | 2 | 0 | 0 | 87% | |
| Jun 1, 2026 | 8 | 6 | 2 | 0 | 0 | 88% | |
| May 1, 2026 | 7 | 6 | 2 | 0 | 0 | 87% | |
| Apr 1, 2026 | 7 | 6 | 2 | 0 | 0 | 87% | |
| Mar 1, 2026 | 7 | 6 | 2 | 0 | 0 | 87% | |
| Feb 1, 2026 | 7 | 6 | 2 | 0 | 0 | 87% |
Price targets
Where 9 covering analysts think PYXS trades over the next 12 months.
$8.67 +305.0% upside Strong Buy
Current$2.14 Low$6.00 Median$8.00 High$19.00 9 analysts
$6.00$19.00
Analyst rating Strong Buy· 1.3/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
9 SEC filing reports analyzed · 1 bullish, 1 bearish, 2 mixed, 5 neutral · avg impact 4.3/10.Plus 3 press releases.
NEUTRAL8-K3/10
Pyxis Oncology appointed interim CEO Thomas Civik as permanent CEO and Chairman, replacing John Flav
Sep 9, 2026
BULLISH8-K6/10
Pyxis Oncology announced positive updated Phase 1 monotherapy data for micvotabart pelidotin (MICVO)
Sep 9, 2026
BEARISHEFFECT6/10
Pyxis Oncology's S-3 shelf registration (File No. 333-298461) became effective on August 27, 2026, a
Aug 28, 2026
MIXED8-K5/10
Pyxis Oncology reported Q2 2026 results with a net loss of $25.3M ($0.40/share), wider than the prio
Aug 13, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 2, 2026
offering
Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering
BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS or the “Company”), a clinical-stage company developing next-generation th
Oct 1, 2026
short_volume
Short Volume: PYXS — 62.7% short (1.1M / 1.8M)
Short: 1,104,674 | Exempt: 97,030 | TRF Vol: 1,761,917 | Short Ratio: 62.7% | Off-exchange volume (dark pool + OTC)
Sep 30, 2026
offering
Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering
BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for d
Sep 30, 2026
short_volume
Short Volume: PYXS — 57.0% short (1.8M / 3.2M)
Short: 1,843,285 | Exempt: 267,667 | TRF Vol: 3,233,946 | Short Ratio: 57.0% | Off-exchange volume (dark pool + OTC)
Sep 9, 2026
short_volume
Short Volume: PYXS — 61.7% short (1.1M / 1.8M)
Short: 1,120,895 | Exempt: 155,524 | TRF Vol: 1,815,756 | Short Ratio: 61.7% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.28 | $-0.36–$-0.22 | 20.6% | -0.4% | 4↑ 3↓ | $0.0B | 9 |
| Next Q | $-0.26 | $-0.38–$-0.18 | 9.6% | +5.6% | 6↑ 1↓ | $0.0B | 9 |
| Current FY | $-1.22 | $-1.49–$-0.99 | 4.7% | +0.3% | 3↑ 5↓ | $0.0B | 9 |
| Next FY | $-1.13 | $-1.70–$-0.73 | 7.6% | +6.1% | 4↑ 3↓ | $0.0B | 9 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.278 | — |
| 7d ago | $-0.278 | — |
| 30d ago | $-0.277 | -0.001 |
| 60d ago | $-0.275 | -0.003 |
| 90d ago | $-0.281 | +0.003 |
Institutional ownership
Which big funds own PYXS (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $26.0M total value (8,633,165 shares) as of 2026-Q2. Top holders: VANGUARD, BlackRock,, MARSHALL. Net buying activity: 11 institutions added/increased vs 4 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 2,075,997 | $6.2M | 24.0% | — |
| BlackRock, Inc. | 867,934 | $2.6M | 10.1% | TRIM -26.2% |
| MARSHALL WACE, LLP | 830,544 | $2.5M | 9.6% | DOUBLED +134.3% |
| RENAISSANCE TECHNOLOGIES LLC | 772,232 | $2.3M | 8.9% | ADD +26.4% |
| GEODE CAPITAL MANAGEMENT, LLC | 591,849 | $1.8M | 6.9% | — |
| Woodline Partners LP | 523,999 | $1.6M | 6.1% | — |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 428,606 | $1.3M | 5.0% | — |
| VANGUARD FIDUCIARY TRUST CO | 302,986 | $912.0K | 3.5% | — |
| JANE STREET GROUP, LLC | 290,090 | $873.2K | 3.4% | TRIM -61.3% |
| STATE STREET CORP | 248,837 | $749.0K | 2.9% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| MARSHALL WACE, LLP | DOUBLED | 354,417 | 830,544 | +134.3% | $2.5M |
| MILLENNIUM MANAGEMENT LLC | TRIM | 397,625 | 233,004 | -41.4% | $701.3K |
| UBS Group AG | TRIM | 254,124 | 155,217 | -38.9% | $467.2K |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 16,807 | 80,464 | +378.8% | $242.2K |
| STIFEL FINANCIAL CORP | ADD | 50,537 | 70,437 | +39.4% | $212.0K |
| Qube Research & Technologies Ltd | DOUBLED | 11,286 | 49,932 | +342.4% | $150.3K |
| LPL Financial LLC | ADD | 33,554 | 43,554 | +29.8% | $131.1K |
| CITIGROUP INC | DOUBLED | 1,740 | 38,205 | +2095.7% | $115.0K |
| SIMPLEX TRADING, LLC | DOUBLED | 253 | 37,902 | +14881.0% | $114.1K |
| DIMENSIONAL FUND ADVISORS LP | ADD | 25,912 | 36,175 | +39.6% | $108.9K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
10 insiders, 20 transactions. Net -$123.0K — $0.00 bought, $123.0K sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | GordonMD Global Investments LP | 10%+ Owner | BUY | 7,546,766 | — | — |
| Oct 1, 2026 | GordonMD Global Investments LP | 10%+ Owner | BUY | 5,517,000 | — | — |
| Sep 4, 2026 | Civik Thomas | CEO & Chairman of the Board | AWARD | 2,503,050 | — | — |
| Aug 20, 2026 | Dupont Jakob | Director | AWARD | 46,000 | — | — |
| Aug 12, 2026 | Civik Thomas | Interim CEO | AWARD | 250,956 | — | — |
| Jun 30, 2026 | Dupont Jakob | Director | SELL | 35,000 | $3.06 | $107.1K |
| Jun 30, 2026 | Dupont Jakob | Director | EXERCISE | 35,000 | $1.60 | $56.0K |
| Mar 24, 2026 | Lewis-Hall Freda C | Director | AWARD | 45,867 | — | — |
| Mar 24, 2026 | FLAVIN JOHN L | Director | AWARD | 45,867 | — | — |
| Mar 24, 2026 | Palani Santhosh | Director | AWARD | 45,867 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for PYXS.
Shares short
4,678,522
Settlement Sep 15, 2026
Change vs prior
+17.9%
Semi-monthly cycle
Days to cover
3.6
At avg daily volume
Of shares outstanding
≈5.6%
Estimate — not % of float
| Halted | Code | Reason | Status |
|---|---|---|---|
| Aug 11, 2026 | LUDP | Volatility Pause | Resumed |
| Aug 11, 2026 | LUDP | Volatility Pause | Resumed |
| Aug 11, 2026 | LUDP | Volatility Pause | Resumed |
| Aug 11, 2026 | LUDP | Volatility Pause | Resumed |
All PYXS filing & press-release reports (12)
- 8-K reportSep 9, 2026
- 8-K reportSep 9, 2026
- EFFECT reportAug 28, 2026
- 8-K reportAug 13, 2026
- 144 reportJul 3, 2026
- 8-K reportJul 2, 2026
- PRESS-RELEASE reportJun 30, 2026
- 8-K reportMay 14, 2026
- PRESS-RELEASE reportMay 14, 2026
- DEFA14A reportApr 30, 2026
- PRESS-RELEASE reportApr 17, 2026
- PRESS-RELEASE reportMar 23, 2026